In this collection, we turn the spotlight inside our heads and focus on the brain and neurochemistry. How do we remember things and feel pain? Are we any closer to a cure for Alzheimer’s? These are some of the questions we’re looking at, as well as in-depths examinations of the chemistry of addiction and how researchers are trying to get around the blood—brain barrier.
Andy Extance looks into the latest in Alzheimer’s disease, pain and memory
Jamie Durrani speaks to researchers exploring how epigenetic changes in the brain affect drug-seeking behaviours
Researchers are on a quest to outsmart and overcome the sophisticated security system of the brain. Julia Robinson reports on some of the approaches being studied
Understanding role of fragments of amyloid protein could lead to novel therapies for the disease
Cell and animal tests suggest two classes of common chemicals might play a role in neurological disease
Our gut microbiome has been linked to conditions such as Parkinson’s and Alzheimer’s. Anthony King reports on the connections
Biogen abandoning Alzheimer’s antibody aducanumab is unusual, but hardly surprising, says Derek Lowe
Human growth hormone extracted from cadavers passed disease protein to at least five people
Efforts to understand how intrinsically disordered regions interact have produced a variety of answers
Companies are convincing regulators, but will doctors use them, and will providers pay for them?
Tau protein fragment could track progress of the disease
The 2019 US approval of antibiotic Recarbrio seems not to have met the normally expected standards
Imitating the way that neurons communicate could lead to low-power neuromorphic computing
Expression recording islands show when and where cells responded
Biogen–Eisai’s lecanemab can slow disease progression a little, but at significant cost and risk of side effects
Tantalising press-released data on Biogen and Eisai’s lecanemab prompt questions without firm answers
Biogen’s aducanumab is stumbling into obscurity. Where does that leave the amyloid hypothesis?
A 2000 year old decapitated Yorkshire man and the ancient proteins in his preserved brain might provide clues to modern diseases, as Hayley Bennett discovers
Were FDA staff unduly influenced by Biogen in approving Alzheimer’s antibody?
Good news for industry and future drug approvals, but physicians doubt it will be effective for most patients
In a discovery that raises more question than it answers, researchers have found zero-oxidation-state iron and copper deposits inside amyloid plaques
From why brains are like search engine algorithms to tips on boosting your memory
Invasive plant and cyanobacterium join up to form a deadly duo that have been killing US wildlife
US FDA advisors vote against approving Biogen’s aducanumab on the basis of incomplete data analysis
Cell-specific electric stimulation could help be used with bioelectronic prostheses or treat diseases like epilepsy